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Abstract
Background: Studies describing the clinical progression of animals with reverse pat-
ent ductus arteriosus (PDA) are lacking.
Objectives: To describe the signalment, presenting signs, echocardiographic
features, and survival in a group of dogs and cats with bidirectional and continuous
right-to-left PDA.
Animals: Forty-six client-owned animals included, comprising 43 dogs and 3 cats with
bidirectional or continuous right-to-left PDA.
Methods: Retrospective multicenter study. Medical records and echocardiographic
findings reviewed from animals diagnosed with bidirectional or continuous right-to-
left PDA. Impact of ductal morphology, spectral Doppler flow profile, PCV, sildenafil
treatment at presentation, sildenafil dose, severity of pulmonary hypertension, gen-
eral anesthesia with or without surgery and the presence of right-sided congestive
heart failure (R-CHF) on crude mortality rate were evaluated via Mantel-Cox log rank
comparison of Kaplan-Meier survival curves. Univariable and multivariable Cox pro-
portional hazards analysis was performed, and hazard ratio (HR) (95% confidence
intervals [CI]) was presented.
Results: Hindlimb collapse was the most common presenting sign in dogs (n = 16).
Clinical signs in cats were variable. Median survival time was 626 days in dogs (range
1-3628 days). Dogs with R-CHF had a shorter median survival time (58 days vs
1839 days, P = .03). Dogs treated with sildenafil at initial presentation survived lon-
ger (1839 days vs 302 days, P = .03), which was the only independent predictor of
survival (HR 0.35, CI 0.15-0.86, P = 0.021).
Conclusions and Clinical Importance: Dogs and cats with reverse PDA have a vari-
able clinical presentation and prognosis. Survival time was longer in animals
Abbreviations: ASD, atrial septal defect; CHF, congestive heart failure; DCRV, double-chambered right ventricle; GA, general anesthesia; LA, left atrium; MDD, minimal ductal diameter; PDA,
patent ductus arteriosus; PH, pulmonary hypertension; PR, pulmonary regurgitation; TR, tricuspid regurgitation; TS, total solids.
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prescribed sildenafil at diagnosis. Dogs with R-CHF at presentation have a worse
overall outcome.
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1 | INTRODUCTION
Patent ductus arteriosus (PDA) is 1 of the most common congenital
cardiac diseases in dogs, accounting for 11% to 30% of congenital
heart defects.1-4 It is less frequent in cats (representing only 3% of
congenital heart defects5-7).
The ductus arteriosus is a vessel that develops from the embry-
onic left sixth aortic arch. Typically, ductal flow decreases dramatically
within the first 12 hours of life in the neonatal dog, ceasing altogether
within 7 days, but in some individuals the ductus can remain patent.8
Direction of blood flow through the PDA is determined by the relative
resistances of the pulmonary and systemic vascular beds. Flow there-
fore typically proceeds from left-to-right, that is, from the aorta to the
pulmonary artery.9 In animals with severe pulmonary hypertension
(PH), pulmonary vascular resistance can exceed systemic vascular
resistance, leading to right-to-left shunting across the PDA, and
mixing of deoxygenated blood in the descending aorta. There is a
spectrum of disease, however, such that blood flow through the PDA
can be continuously right-to-left or bidirectional, influenced by the
severity of PH and systemic vascular resistance. Pulmonary hyperten-
sion and “shunt reversal” is a relatively uncommon complication,
occurring in approximately 1% to 6% of dogs with PDA.8,10,11 Cats
appear to be more vulnerable to the development of PH,12 with
reverse or bidirectional shunting occurring more frequently in this
species (15%-17% of cats with PDAs13,14).
The etiology and timing of shunt reversal in dogs and cats with
PH and PDA are poorly characterized and unpredictable. Increased
endothelial shear stress due to augmented pulmonary blood flow can
result in reactive vasoconstriction, progressive medial hypertrophy,
intimal proliferation of the pulmonary vasculature, and shunt reversal
(Eisenmenger's physiology).1,15,16 In 1 colony of dogs,17 PH and rever-
sal of shunting developed within the first few weeks of life. Shunt
reversal occurs after left-sided congestive heart failure (CHF) in
dogs18 (but has not, as yet, been reported in cats) while others have
presented with no prior indication of their congenital heart disease.
Polycythemia is a well-recognized consequence of hypoxemia in
animals with cyanotic congenital heart disease and the ensuing
hyperviscosity, as opposed to CHF, is the most commonly reported
cause of disease and death in animals with right-to-left PDA.19 The
need for frequent interventions (such as phlebotomy) to target poly-
cythemia can be poorly tolerated by some animals,15,20 and can result
in serious owner concerns about the animal's quality of life.
There is paucity of information regarding the natural history and
optimal treatment strategies for dogs and cats with reverse PDA.
Information in the literature is limited to individual case reports,21-24
small case series9,11,15,25 or larger retrospective studies of PDA that
include a small number of cases with continuous right-to-left or bidi-
rectional flow through the ductus.3,13,14,26 The aim of this study is to
describe the signalment, presenting complaints, echocardiographic
features, treatment, and survival time in a referral population of dogs
and cats with bidirectional and continuous right-to-left PDA.
2 | MATERIALS AND METHODS
This is a retrospective, multicenter cohort study. Ethical approval was
sought from the Social Sciences Research Ethical Review Board (URN
SR2019-0080) at the Royal Veterinary College (RVC). Medical records
from Southern Counties Veterinary Specialists, the RVC Queen
Mother Hospital for Animals, Davies Veterinary Specialists and the
University of Liverpool Small Animal Teaching Hospital were searched
for dogs and cats examined between November 2003 and September
2019, using the key terms “reverse patent ductus arteriosus,” “bidi-
rectional patent ductus arteriosus” and “right-to-left patent ductus
arteriosus.” Dogs and cats were included in the study if they had been
diagnosed with a continuous right-to-left or bidirectional shunting
PDA by a board-certified cardiologist or resident under their supervi-
sion. If the PDA was not visualized at the time of echocardiographic
examination, a positive result after contrast echocardiography,
assessed via the injection of agitated saline for a bubble study, was
required to verify the presence of continuous right-to-left or bidirec-
tional shunting. The term “reverse” PDA is used to describe cases
with either continuous right-to-left or bidirectional PDA.
Information was collected regarding signalment, presenting signs,
radiographic and echocardiographic findings, treatment and survival
status.
All echocardiographic measurements were performed by a board-
certified cardiologist or supervised cardiology resident. Where avail-
able, echocardiographic data recorded included the presence or
absence of subjective concentric right ventricular hypertrophy (right
ventricular wall thickness subjectively equal to or exceeding left ven-
tricular wall thickness), flattening of the interventricular septum and
concurrent congenital cardiac disease. Left atrial (LA) size was quanti-
fied using the LA diameter to aortic root diameter ratio (LA : Ao), mea-
sured from the right parasternal short axis view at the level of the
heart base, the first frame after aortic valve closure.27
Ductal morphology was characterized according to the Miller
classification system.28 The inner edge-to-inner edge method was uti-
lized to measure ductal dimensions: The minimal ductal diameter
(MDD) was considered the width of the ductus at its most narrow
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diameter.28,29 Results of ductal spectral Doppler interrogation were
recorded. Where present, maximal tricuspid regurgitation (TR) and
pulmonary regurgitation (PR) velocities (Vmax) were used to quantify
pulmonary systolic and mean diastolic pressure using the modified
Bernoulli equation (the instantaneous pressure gradient = 4v,2 where
v is the maximal velocity measured in m/s30,31). Estimated right atrial
pressure was not accounted for, so minimum values for systolic pul-
monary artery pressure were recorded. Pulmonary hypertension was
confirmed when peak velocities exceeded 3 m/s, for TR, or 2.2 m/s,
for PR, in the absence of right ventricular outflow tract
obstruction.30,32,33
Contrast echocardiography, performed via injection of agitated
saline into a peripheral vein, was used to visualize the passage of con-
trast through the abdominal aorta.30,34 Visualization of contrast within
the descending aorta was required for verification of reverse PDA in
cases where spectral Doppler interrogation of the ductus was not
available, in the absence of a concurrent right-to-left intracardiac
shunt. Cases with concurrent intracardiac right-to-left shunting, deter-
mined by the presence of echodense contrast within the left side of
the heart, were recorded.34 The presence or absence of arrhythmias
was determined from available paper ECG recordings, ECGs, or both
recorded concurrently to echocardiographic examinations.
Packed cell volume and total solids (TS) were determined by cen-
trifugation of fresh whole blood in heparinized microcapillary tubes
and were recorded at the time of presentation.9
Where additional diagnostic tests were performed to explore for
possible causes of PH, details of the tests and results were recorded.
Available thoracic radiographs were reviewed by a board-certified
radiologist or supervised resident at the time of presentation. Informa-
tion on cardiac size and radiographic lung pattern were obtained from
radiographic reports.
Details of medications prescribed at initial presentation were
recorded. This included treatment with sildenafil (Viagra, Pfizer,
U.S. Pharmaceuticals, New York, New York), myelosuppressive agents,
and any other oral or parenteral medications. When phlebotomy was
performed, preprocedural and postprocedural PCV were documented in
addition to the total volume of blood removed. Information on any sur-
gical or minimally invasive interventional procedures were documented.
Survival data were obtained from clinical records. Where the date
or cause of death was not documented, referring practices were con-
tacted between August and September 2019 to establish the out-
come for each dog and cat.
2.1 | Statistical analysis
Descriptive statistical analysis was performed on the data collected
from the medical records and analyses were performed using com-
mercially available software (BM SPSS Statistics 21.0 for Windows
7, IBM (UK) Ltd, Portsmouth, UK; GraphPad Prism 6, GraphPad Soft-
ware Inc, San Diego, California). Continuous data were assessed for
normality using the Shapiro-Wilk test. Normally distributed data are
presented as mean (±SD) and nonnormally distributed data are
reported as median [range]. Median PCV values were compared
between dogs grouped according to initial presenting signs using the
Kruskal-Wallis test, with the Dunn test used for post hoc pairwise
comparisons.
Kaplan-Meier survival curves were generated to assess the
impact of ductal morphology, PCV, sildenafil administration at presen-
tation, sildenafil dose, severity of PH, anesthesia (with or without sur-
gery) and the presence of R-CHF on median survival time. Data were
censored if the animal was still alive or lost to follow-up at the end of
the study period and survival times were reported as medians (range).
Differences between groups were analyzed using the Logrank
(Mantel-Cox) test.
For the Cox proportional hazards model, variables were also
dichotomized using cut-offs derived from the median values and were
taken forward to the multivariable analysis as categorical data. Vari-
ables with a P value <.2 on univariable analysis were entered into a
multivariable Cox regression analysis using a manual forward selection
method to identify independent predictors of survival. The variable
with the lowest P value was entered into the model at each iteration.
The order in which variables were entered into the model was based
on the strength of their association, with covariates with the lowest
P values from the previous step entered first. Hazard ratios (HR) and
95% confidence intervals (CI) for the Cox regression were presented.
A statistically significant result was defined as a P value <.05.
3 | RESULTS
Forty-six animals met the inclusion criteria, comprising 43 dogs and
3 cats. Signalment data are summarized in Table 1. Of the dogs, the
TABLE 1 Demographic features and presenting signs for dogs
and cats with reverse patent ductus arteriosus (PDA)
Demographic and presenting signs
Variable Dogs, n = 43 Cats, n = 3
Age (months) 11.0 [44.0-140.0] 42.7 (± 22.7)
Females 34 2
Body weight (kg) 6.6 [3.9-9.4] 3.4
Presenting signs
Free from clinical signs 4 1
Hind limb collapse 16 —
Exercise intolerance 9 —
Abdominal distension 3 1
Signs of neurological disease 3 —
Syncope 3 —
Tachypnoea, dyspnoea, or both 1 1
Cough 2 —
Signs of gastrointestinal disease 2 —
Note: Normally distributed data are presented as mean (±SD) and
nonnormally distributed data are reported as median [range].
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breeds represented were Jack Russell Terrier (n = 9), Crossbreed
(n = 5), Chihuahua (n = 3), Pembroke Welsh Corgi (n = 3), Border Ter-
rier (n = 2), Shetland Sheepdog (n = 2), Patterdale Terrier (n = 2), and 1
each of the following: Border Collie, Greyhound, Havanese, Hungarian
Vizsla, Italian Spinoni, Labarador Retriever, Lakeland Terrier, Lhasa
Apso, Miniature Dachshund, Norwich Terrier, Old English Sheepdog,
Pyrenean Shepherd, West Highland White Terrier, Yorkshire Terrier,
Dachshund, Toy Poodle, and Shih Tzu. Two Siamese cats and
1 Domestic Shorthair were included in the study.
Receiving services at presentation included cardiology (n = 25),
internal medicine (n = 11), neurology (n = 6), and emergency critical
care (n = 4). Initial presenting signs were recorded for all 46 cases and
are summarized in Table 1. The most common presenting signs in
dogs were hindlimb collapse (n = 16) and exercise intolerance (n = 9).
The 3 dogs with abdominal distension had ascites secondary to R-
CHF. The neurological signs reported in 3 dogs included forebrain
signs (circling), acute onset vestibular signs and seizures. Presenting
complaints in cats included tachypnoea (n = 1), abdominal distension
(n = 1) and 1 cat was free of clinical signs.
Only 1 dog had a continuous murmur prior to referral. Auscul-
tation abnormalities at presentation included a split or loud second
heart sound in 15 dogs, 4 of which had a concurrent heart murmur.
Eighteen dogs had a heart murmur in the absence of S2 abnormali-
ties. Three dogs had a diastolic component in addition to a systolic
component and 1 of these dogs also had a loud S2. Murmur point
of maximum intensity was variably reported. Ten dogs had no
abnormalities reported after cardiac auscultation. Two cats had
heart murmurs and 1 had a split second heart sound. Fifteen ani-
mals (14 dogs and 1 cat) had a murmur reported in their previous
history. Differential cyanosis was assessed in 26 dogs and present
in 11 out of 26 dogs.
Electrocardiography was performed in 20 dogs and right mean
electrical axis deviation was the most frequently reported abnormality
(n = 11). Additional electrocardiographic abnormalities included iso-
lated ventricular premature complexes (n = 1), paroxysmal supraven-
tricular tachycardia (n = 1) and sinus arrhythmia with second degree
atrioventricular block in a dog that had been sedated with
butorphanol prior to echocardiographic examination.
Packed cell volume and TS recorded on presentation were 60%
(±13.13) and 63.35 g/L (±7.95), respectively. The median PCV was
compared between dogs grouped according to 4 common presenting
signs (hindlimb collapse, exercise intolerance, neurological signs, and
dogs who were asymptomatic at presentation). Dogs who had neuro-
logical signs at presentation had a significantly higher PCV compared
to those who were asymptomatic (P = .01, Figure 1).
Thoracic radiographic reports were available for review in 32 ani-
mals (30 dogs and 2 cats). Abnormalities included right-sided cardiac
enlargement in 30 animals, with normal pulmonary opacity (17 dogs
and 1 cat) and increased pulmonary opacity (11 dogs and 1 cat),
respectively. Bilateral cardiac enlargement with a bronchointerstitial
pattern was present in 1 dog and a diffuse interstitial lung pattern
with no reported cardiac enlargement in another dog. Of the 12 ani-
mals with right-sided cardiac enlargement and increased pulmonary
opacity, the following lung patterns were described: interstitial (n = 1),
bronchointerstitial (n = 5), patchy pulmonary infiltrate (n = 3, including
1 cat), alveolar pattern (n = 1), and a nonspecific increase in pulmonary
opacity (n = 2). In 16 cases, dilation of the main pulmonary artery was
reported.
Echocardiography was performed in all 46 animals. Direct visuali-
zation of the ductus was achieved and recorded in 39/46 cases. The
distribution of ductal morphology types is presented in Table 2. Two
cats had a type III and 1 cat had a type IIb ductus. The mean minimal
ductal diameter of the entire study sample was 6.14 mm (±2.78).
Spectral Doppler flow profiles were available for review in 35 animals
(32 dogs and 3 cats) and showed continuous right-to-left shunting
and bidirectional flow in 16 dogs each, respectively. All 3 cats had
bidirectional flow across the ductus. Concentric right ventricular
hypertrophy was present in 40 dogs and 3 cats. Septal flattening was
assessed in 30 animals (29 dogs and 1 cat) and was present in all
cases. Left atrial size according to LA : Ao for the entire group was
1.28 (±0.26) (see Table 3). Additional congenital cardiac abnormalities
included tricuspid valve dysplasia in 4 dogs, patent foramen ovale
(right-to-left shunting), persistent left cranial vena cava and mitral ste-
nosis in 1 dog each, respectively. The severity of mitral stenosis was
not described. A bubble study was performed to verify the presence
of the persistent left cranial vena cava, through the injection of agi-
tated saline via the left cephalic vein. One cat had a double-
chambered right ventricle (DCRV) and right-to-left shunting across an
atrial septal defect (ASD).
Contrast echocardiography was performed in 36 dogs and 2 cats.
In the remaining 7 dogs and 1 cat, spectral Doppler profiles across the
ductus were available for review for verification of continuous right-
F IGURE 1 Median PCV values of dogs grouped according to
initial presenting signs of hindlimb collapse, signs of neurological
disease, exercise intolerance, and dogs who were asymptomatic
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to-left or bidirectional shunting. A positive result, determined by the
presence of contrast in the abdominal aorta, was present in 33 dogs.
In 2 dogs, contrast could not be visualized in the descending aorta,
but bidirectional flow was confirmed across the ductus on spectral
Doppler traces. In 1 dog and 2 cats, the aorta was not assessed during
contrast echocardiography (only the heart for concurrent intracardiac
shunting); however, spectral Doppler profiles were also available for
these cases.
Pulmonary hypertension was confirmed in 34 cases (32 dogs and
2 cats) via spectral Doppler interrogation of tricuspid and PR veloci-
ties. Mean TR velocity and PR velocity were 5.14 m/s (±0.72) and
3.90 m/s (±0.59), respectively. Investigations to establish the etiology
of PH were performed in 14 dogs and included Baermann fecal flota-
tion (n = 6), IDEXX Angio Detect (n = 1), Baermann and IDEXX Angio
Detect (n = 5), Baermann and SNAP 4Dx serology screen for
Dirofilaria immitis (n = 1), D-dimers and urine-protein-creatinine ratio
(n = 1). Results were unremarkable apart from in 1 dog with
unexplained proteinuria, in which urine sediment evaluation and cul-
ture were both negative. In this dog, hypercoagulability or potential
thromboembolic disease could not be confirmed or rejected as a pos-
sible cause of PH.
Thirty-two dogs and 1 cat received sildenafil on presentation. The
median total dose of sildenafil was 3.0 mg/kg/d [1.8-5.1]. Twenty-
three animals received additional medications including pimobendan
(n = 8), bosentan (n = 1), furosemide either alone (n = 1), or in combi-
nation with benazepril, clopidogrel, aspirin, pimobendan and spi-
ronolactone (n = 4), fenbendazole alone (n = 1), or in combination with
potentiated amoxicillin or trimethroprim sulphonamide (n = 2),
hydroxyurea alone (n = 2), or with terbutaline (n = 1) and 1 dog was
treated with clopidogrel alone (n = 1). One dog presenting with sei-
zures was treated with phenobarbital.
Therapeutic phlebotomy was performed in 13 dogs, the PCVs of
which ranged from 65% to 90% with a mean of 73.9%. The total vol-
ume of blood collected was only available for 8/13 dogs, with a
median value of 10.0 mL/kg [8.9-19.0]. Medical leech phlebotomy
was performed in 1 dog (a Pembroke Welsh Corgi) after traditional
phlebotomy had been performed on 3 occasions, reducing her PCV
from 67% to 56%. Records of total PCV reduction after phlebotomy
were only available for 4 dogs: 2 Jack Russell Terriers, from 78% to
67% and 72% to 60%, respectively, and 1 Norwich Terrier, from 70%
to 58%. A Patterdale Terrier underwent phlebotomy, which reduced
his PCV 90% to 67%, but the volume removed was not recorded.
Survival information was available for 38 animals. The remaining
8 were lost to follow-up. At the time of data collection, 12 animals
were alive and 26 had died. The median survival time for dogs was
626 days (range 1-3628, Figure 2). The median survival time was not
calculated in cats due to the low numbers included. Their individual
survival times were 1, 8, and 2473 days.
Sixteen dogs were euthanised. The reasons for euthanasia
included progressive dyspnoea (n = 3), unspecified progressive clinical
signs (n = 7), haemorrhagic gastroenteritis and hypovolaemic shock
(n = 1), owner decision not to treat at time of diagnosis (n = 1), renal
disease (n = 1), seizures (n = 1), but was not recorded in 2 dogs. Five
dogs died without euthanasia. The cited cause of death included a
road traffic accident (n = 1), unexpected death after collapse at home
(n = 1) and death due to unknown cause in 3 dogs. Five animals died
during or shortly after general anesthesia (GA). In 3 of these cases,
closure of the ductus had been attempted. A West Highland White
Terrier developed progressive dyspnoea after surgical ligation of the
ductus and cardiopulmonary arrest occurred 7 days after surgery.
Minimally invasive closure of the ductus was attempted using the
TABLE 3 Specific echocardiographic measures of pulmonary
hypertension, ductal diameter, and left atrial size in dogs and cats
Echocardiographic findings
Variable Result
MDD type II 5.30 mm (±2.45)
MDD type III 6.85 mm [4.90-8.87]
MDD overall 6.14 mm (±2.78)
TR maximal velocity 5.14 m/s (±0.72)
PR maximal velocity 3.90 m/s (±0.59)
LA : Ao 1.28 (±0.26)
Note: Normally distributed data are presented as mean (±SD) and
nonnormally distributed data are reported as median [range].
Abbreviations: LA : Ao, left atrial to aortic ratio; MDD, minimal ductal
diameter; PR, pulmonic regurgitation; TR, tricuspid regurgitation..
F IGURE 2 Kaplan-Meier curve to show overall survival of dogs
with bidirectional or right-to-left shunting patent ductus
arteriosus (PDA)
TABLE 2 Ductal morphology grouped according to the Miller
classification system in dogs and cats





aUnable to access echo to confirm patent ductus arteriosus (PDA)
morphology (n = 8), PDA not visualized at the time of echo (n = 7), and
poor-quality image of the ductus (n = 2).
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Amplatz canine duct occluder in a greyhound, but the procedure was
aborted due to instability under GA. Surgical closure of the ductus
was attempted in the same dog 4 weeks later, but it developed ven-
tricular fibrillation at the time of ductal ligation and died. One cat
experienced major hemorrhage at the time of ductal ligation and died
in theater.
Two animals died during GA that was unrelated to any attempt to
close the ductus: One dog (a Shih Tzu) died after intubation for surgi-
cal management of a compressive spinal cord lesion between L4 and
L7 due to suspected hemorrhage. Frank blood was visualized in the
endotracheal tube and the surgery was not attempted. The dog died
shortly afterwards, and signs were attributed to a coagulopathy. The
cat with concurrent right-to-left shunting ASD and DCRV was anes-
thetized for cardiac catheterisation and transoesophageal echocardi-
ography. She developed third-degree atrioventricular block and
profound hypoxemia under anesthesia and died after failed cardiopul-
monary resuscitation. Five of the 6 animals in which shunt closure
was attempted received sildenafil preoperatively; the cat who died
after hemorrhage during duct ligation did not receive sildenafil. The
sildenafil dose range was 2.5 to 15 mg/kg/d. Successful ductal ligation
via surgical ligation was achieved in 3 cases: a Siamese cat and
Chihuahua, who were both alive at the time of data collection
(follow-up 2473 and 966 days, respectively), and a Jack Russell Terrier
who was lost to follow-up, but was last known to be alive at 74 days
postsurgery.
Neither ductal flow (whether bidirectional or continuous right-to-left)
or ductal morphology (type II vs type III) influenced outcome (P = .78 and
P = .25, respectively). Likewise, TR velocity (>5.14 m/s) and PCV at
presentation (>60%) had no impact on outcome (P = .36 and P = .62,
respectively). Dogs that were treated with sildenafil at presentation lived
longer than those without (1839 days vs 302 days, P = .03, Figure 3);
however, the dose of sildenafil did not impact survival (562 days vs
1839 days, P = .91, Figure 4). Dogs with R-CHF at presentation had a
worse survival (58 days vs 1839 days, P = .03, Figure 5). When comparing
dogs that underwent GA with or without surgical closure of the ductus to
those who did not, there was no significant difference in out-
come (P = .11).
Presence of R-CHF (P = .04), treatment with sildenafil (P = .021),
age ( = 0.06), and minimum ductal diameter (P = 0.20) were evaluated
in multivariable Cox regression. Treatment with sildenafil was the only
independent predictor of crude mortality rate (HR 0.35, CI 0.15-
0.86, P = .02).
4 | DISCUSSION
This multicenter study describes the natural history and outcome of
dogs and cats with reverse PDA. In agreement with previous reports,
presenting signs were variable.9,15 It is therefore unsurprising that ani-
mals were referred to a variety of disciplines, including neurology,
internal medicine, and emergency critical care. This wide range of clin-
ical presentations adds to the diagnostic challenge in evaluating dogs
and cats with reverse PDA.
Survival times for dogs with R-CHF were short, although this was
a complicating factor in only a small number of cases. Right heart
function is challenging to determine with echocardiography due to
the complex geometry of the right ventricle35,36; however, the pres-
ence of R-CHF is suggestive of secondary right-sided myocardial
F IGURE 3 Kaplan-Meier curves to explore the difference in
median survival time between dogs treated with sildenafil and those
not treated with sildenafil in dogs with bidirectional or right-to-left
shunting patent ductus arteriosus (PDA)
F IGURE 4 Kaplan-Meier curves to explore the difference in
median survival time between dogs receiving sildenafil dose
<3 mg/kg/d and those receiving sildenafil dose ≥3 mg/kg/d in dogs
with bidirectional or right-to-left shunting patent ductus
arteriosus (PDA)
F IGURE 5 Kaplan-Meier curves to explore the difference in
median survival time between dogs in right-sided congestive heart
failure (R-CHF) compared to those without R-CHF in dogs with
bidirectional or right-to-left shunting patent ductus arteriosus (PDA)
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dysfunction in these animals (although the impact of concurrent right-
sided congenital disease, such as TVD, cannot be excluded). The
development of R-CHF is also a poor prognostic indicator in dogs with
pulmonic stenosis (rather than PH),37-39 and worse outcomes are simi-
larly reported in people with R-CHF due to Eisenmenger's physiol-
ogy.40 Interestingly, in this study, median survival time in dogs with
bidirectional and right-to-left PDA without R-CHF at the time of pre-
sentation was greater than 5 years, suggesting that dogs without R-
CHF can have a good prognosis despite having reverse PDA.
Estimated pulmonary arterial pressures were not predictors of
death in this study sample, but are independently associated with sur-
vival in people with Eisenmenger syndrome, alongside World Health
Organization functional class for PH and treatment with sildenafil.41
Pulmonary hypertension can result from persistence of the foetal pul-
monary circulation, development of acquired lesions or a combination
of both mechanisms.8,11,17,18,42,43 Several factors including the nitric
oxide pathway can contribute to the development of acquired
PH.44,45 Sildenafil citrate facilitates nitric oxide-cyclic guanosine
monophosphate (cGMP)-induced vasodilatation by inhibiting the deg-
radation of cGMP. There is currently no licensed preparation available
for use in dogs; however, a number of studies have described its use
in dogs with PH.25,32,46,47 Information regarding the use of sildenafil
in a large group of dogs with reverse PDA was previously lacking,
although in 1 small case series of 5 dogs with reverse PDA,25
New York Heart Association functional class significantly improved
after 1 and 3 months of sildenafil and PCV significantly decreased
after 3 months of treatment.25 In our study, treatment with sildenafil
(but not dose) was the only independent prognostic predictor of sur-
vival in dogs. This is challenging to interpret given the study's retro-
spective design and the reasons for prescribing this medication to
specific animals may be affected by unknown bias. These results are
in agreement, however, with studies investigating treatment of people
with Eisenmenger physiology, in whom the use of pulmonary
vasodilators (bosentan and sildenafil) have been demonstrated to be
independently associated with survival.48 One study demonstrated that
1- and 3-year survival rates are significantly higher in people treated
with sildenafil vs those receiving conventional treatment (digoxin,
diuretics, and anticoagulants).41 In this study, sequential echocardio-
graphic estimates of pulmonary arterial pressures after the introduction
of sildenafil and any dose adjustments performed over time were
inconsistently reported. Consequently, we are unable to assess the
impact of these factors on survival, which is a limitation of this study.
In dogs and cats, there is a general consensus that ductal closure is
contraindicated with right-to-left shunting PDAs.9 Complete attenuation
of the shunt precludes access of the right ventricular blood into the sys-
temic circulation, markedly increasing right ventricular afterload, risking
shock, and possible death.8 Treatment has therefore focused on amelio-
ration of clinical signs of hypoxemia and correction of polycythemia to
reduce blood viscosity and improve tissue perfusion.15
Previous studies have reported successful closure of PDA in ani-
mals with PH, but continuous left-to-right shunting was present in all
cases. There are no reports of successful occlusion of right-to-left
shunting PDAs in the literature. Six animals (4 dogs and 2 cats) in our
study underwent attempted closure of the ductus. Five of the 6 ani-
mals in which shunt attenuation was attempted received loading
treatment with sildenafil and all 6 had bidirectional shunting on spec-
tral Doppler interrogation prior to closure. Three animals died during
or in the immediate post-operative period, but those that survived
surgery with follow-up (3) had good long-term survival.
Determination of the reversibility of vascular lesions is key to the
decision-making process in people with congenital cardiac shunts with
PH prior to closure. Lung biopsy, hemodynamic changes during test
occlusion, and response to pulmonary vasodilators are used to evalu-
ate the reversibility of pulmonary vascular disease.49,50 The most
severe vascular changes accompanying PH, such as fibrinoid necrosis
or plexiform lesions, are considered irreversible.8,17,51 People with
severe histologic changes, poorly responsive pulmonary vascular beds,
or worsened pulmonary arterial pressure with test occlusion are typi-
cally considered inoperable.49 Test occlusion at the time of surgical
ligation has been described in 1 cat with PH and continuous left-to-right
shunting PDA.12 Invasive right ventricular pressures were measured
simultaneously and did not increase after test occlusion. Lung biopsy per-
formed at the time of thoracotomy revealed histopathological arterial
changes consistent with PH (smooth muscle hypertrophy of small pulmo-
nary arteries) but no arteritis or plexiform lesions.12 It could be postu-
lated that reasons for excellent tolerance after PDA closure in this cat
and in the animals who survived surgical ligation in our study, are due to
reversible pulmonary vascular disease.
Treatment targeting secondary polycythemia has been considered
the cornerstone of management of dogs with reverse PDA, aiming to
maintain the PCV below a threshold of 65%.8 Only 13 dogs received
phlebotomy in our group and the clinical rationale (ie, whether based
on PCV or clinical signs) was not always documented. The median pre-
senting PCV in our study was relatively low (60%, 36%-90%), which
might explain why phlebotomy was infrequently recommended. In
people with polycythemia caused by right-to-left cardiac shunts, phle-
botomy is reserved for symptomatic patients, even when the patient
PCV exceeds 70%.52 As the effects of phlebotomy are transient, and
sequelae such as iron deficiency can develop, phlebotomy is rec-
ommended for temporary relief of hypervisocity symptoms and not
for hematocrit level per se. In summary, phlebotomy is not rec-
ommended routinely in asymptomatic/mildly symptomatic human
patients, regardless of hematocrit.53-55 Similarly, best practice for
managing polycythemia in dogs remains unclear. Dogs with signs of
neurological disease at presentation had a significantly higher PCV
compared to those who were asymptomatic. This difference, how-
ever, should be interpreted with caution due to the small number of
dogs included within both of these groups. All 3 dogs with signs of
neurological disease underwent phlebotomy.
Three dogs were treated with hydroxyurea for the management
of polycythemia, 2 of which underwent concurrent phlebotomy.
Hydroxyurea is recommended for the treatment of polycythemia in
dogs, cats, and humans.15,56 Despite a number of potential advan-
tages of hydroxyurea over phlebotomy in polycythemic animals
(avoidance of weakness and reduced risk of iron deficiency),57 adverse
effects can include anorexia, vomiting, bone marrow hypoplasia, and
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alopecia. This, in combination with the study sample's relatively low
PCV at presentation, might explain the infrequent use of mye-
losuppressive agents in this study group.
We know that studies utilizing multidimensional imaging to evalu-
ate ductal geometry and dimensions have demonstrated that the
Miller classification system (derived from angiographic studies), might
be inappropriate in classifying ductal morphology due to the highly
variable and unusual appearances of PDA in dogs. Unfortunately,
transesophageal echo and angiography were performed infrequently,
and therefore, more detailed evaluation of ductal geometry in these
dogs and cats is lacking.
Reasons for attempting to describe morphology in this group, is
that traditionally, dogs with a cylindrical, nontapering ductal morphol-
ogy were considered to be at higher risk for developing right-to-left
shunting compared to those with a tapering, funnel-shaped ductus.1
Thus, dogs with large, tubular PDA, and higher shunt fractions might
have increased risk of developing Eisenmenger's physiology. It is inter-
esting that in our study, however, a number of individuals were
included with a type II or tapering ductal morphology (12 vs 17 with
type III), albeit using a classification system that has inherent
limitations.28
There are several limitations of this study, many of which relate
to its retrospective design. The images from a number of digitally
stored echocardiographic examinations were corrupted and
unavailable for review. In 7 cases, the PDA was not visualized at the
time of echocardiographic assessment and diagnosis was based on
compatible clinical signs, supportive echocardiographic findings and a
positive result following bubble study, after exclusion of intracardiac
right-to-left shunts. Consequently, relying on the latter for diagnosis
could have led to the inclusion of other forms of pulmonary-to-systemic
shunts or pulmonary arteriovenous malformations that result in micro-
cavitations bypassing the pulmonary capillaries and entering the
descending aorta. Ductal velocities generated from Doppler inter-
rogation to estimate pressure gradients between the pulmonary
artery and aorta were inconsistently recorded. Ampulla diameter
data were variably recorded and therefore ratios such as MDD:
ampulla diameter could not be calculated. Radiographic findings were
taken directly from reports, which might result in underreporting of cer-
tain abnormalities. Introduction of medical treatment was uncontrolled
and based on the preference of the clinician managing the case. Sec-
ondary causes of PH were infrequently investigated or reported. The
clinical signs associated with reverse PDA can be extremely variable
and differentiating between cardiac causes and noncardiac causes of
death can be extremely challenging. Consequently, crude mortality rate
rather than cardiac mortality was evaluated during our survival analysis.
Longitudinal follow-up varied according to clinician preference and
owner compliance.
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